Dan Stanton

Better returns across cost, speed, and quality and a map modeled on London’s Underground form industry group BioPhorum’s push for why the industry needs a shared technology maturity model.

A peer-reviewed pilot study from WuXi Biologics suggests existing fed-batch facilities could achieve an eightfold improvement in downstream processing capacity by swapping column chromatography for membrane-based alternatives.

A hybrid model built into commercial software and running a self-driving bioreactor has found that unmeasured cellular waste, not the usual metabolites, throttles perfusion yields.

Sponsored by Avid Bioservices, Fujifilm Biotechnologies, IDBS, Lifecore, Lonza, Stellix, and Valgenesis

Large stainless-steel projects are rising, but pipeline demand is increasingly moving toward smaller, more flexible manufacturing models. September 15, 2026 Contributing Writer Topics

“The phrase that I've shamelessly stolen* is that big pharma M&A is the new biotech initial public offering (IPO),” he told attendees of the

Section 232 drug tariffs are expected to accelerate the shift toward domestic manufacturing, but smaller drugmakers may find themselves competing for limited capacity at CDMOs that are increasingly being outmatched by big pharma, according to an industry trade group. September 29, 2026 Contributing Writer Add us as a preferred source on Google Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Two of India's biologics manufacturers say stronger data analytics is cutting the number of questions regulators ask about their intensified processes.

Connecting existing downstream steps delivers the value of continuous bioprocessing, says executive Jon Coffman at BioProcess International in Boston.

“The word ‘continuous’ has fallen out of favor,” said Jon Coffman, executive director of bioprocess technology and engineering at AstraZeneca. He discussed